menu ☰
menu ˟

Invokana added to antihyperglycemics benefits patients with type 2 diabetes

31 Dec 2015
The sodium-glucose cotransporter 2 inhibitor Invokana reduced HbA1c, body weight and blood pressure for adults with type 2 diabetes already assigned DPP-IV inhibitor or glucagon-like peptide-1 receptor agonist therapies, according to research in Diab...

Click here to view the full article which appeared in Endocrinology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.